Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by chrispion Feb 10, 2021 7:25am
118 Views
Post# 32522337

RE:RE:RE:RE:New Zacks Report - $0.60 USD/Share Price Target

RE:RE:RE:RE:New Zacks Report - $0.60 USD/Share Price Targetanalysts can be extremely conservative in their price targets and can be totally off in under-appreciating the share price appreciation that can happen when a biotech releases great data results. Take Ocugen (OCGN) for example, just in the past two weeks they recently released some results and partnership news.

On Feb 1/2021 OCGN closed at $1.81
<study results and partnership news announced in this timeframe>
On Feb 4/2021, with the stock trading at $2.81 H.C. Wainwright sets a tgt price of $4.50
On Feb 8/2021 OCGN closed at $15.81
On Feb 9/2021, with the stock trading at $15.81 Chardan Capital Markets took their tgt price from $0.70 (yes, seventy cents) to $13.


Feb 9/2021
Ocugen downgraded to Neutral at Chardan Capital Markets on share price appreciation; tgt raised to $13 (15.81 ) : Chardan Capital Markets downgrades OCGN to Neutral from Buy and raises their tgt to $13 from $0.70. Analyst Keay Nakae said, "Given the recent significant appreciation in the price of OCGN we are downgrading our rating to Neutral. The stock has increased from $0.29 to $15.81 since announcing on 22 December 2020 its intention to co-develop Bharat Biotech's Covid-19 vaccine candidate, COVAXIN, for the U.S. market. Under the agreement, Ocugen will have U.S. rights to the vaccine candidate and will be responsible for obtaining FDA Emergency Use Authorization (EUA) for COVAXIN. What this will require is uncertain at this point, including the possibility of an additional U.S. based study, but will certainly be highly dependent on the results from the ongoing phase III study in India. Topline data from this study is expected in March 2021. Ocugen will also be responsible for establishing manufacturing of the vaccine in the U.S. and for all this will be entitled to 45% of the profits from U.S. sales."

Feb 4/2021
Ocugen upgrade details -- to Buy at H.C. Wainwright; tgt $4.50 (2.81 ) : H.C. Wainwright upgrades OCGN to Buy from Neutral and sets target price at $4.50. Analyst Swayampakula Ramakanth commented, "On February 2, Ocugen announced that the company has entered into a definitive agreement with Bharat Biotech (private) to co-develop, supply, and commercialize Bharat's COVID-19 vaccine, COVAXIN, for the U.S. market. Recall, on December 22, Ocugen signed a binding letter of intent with Bharat regarding the U.S. rights to COVAXIN. Under the terms of the agreement, Ocugen is responsible for clinical development, regulatory approval, including the Emergency Use Authorization (EUA) and commercialization of the vaccine candidate for the U.S. market. Bharat expects to supply initial doses of COVAXIN for the U.S. market if a EUA is granted. Meanwhile, the parties expect to start the process of technology transfer for U.S. manufacturing. In exchange, Bharat is entitled to share the profits from the sale of COVAXIN in the U.S., with Ocugen retaining 45% of the profits. COVAXIN, a whole-virion inactivated COVID-19 vaccine candidate, has generated promising Phase 1 & 2 data in the studies conducted in India, and received a EUA from the Indian regulator in January. The vaccine induced comparable levels of neutralizing antibodies to those in human convalescent serum, which we believe bodes well for the success of the ongoing Phase 3 trial in India. According to management, the Phase 3 study has fully enrolled 25,800 subjects, and expects to report the to-pline data in 1Q21, which we believe could be a major catalyst."
<< Previous
Bullboard Posts
Next >>